Nonetheless, there is an ongoing Phase III clinical trial testing midostaurin with induction chemotherapy in newly diagnosed AML with FLT3-ITD (clinicaltrials.gov NCT00651261). The gene discussed is FLT3; the disease is acute myeloid leukemia.